Tarsus Pharmaceuticals (NASDAQ:TARS) Trading 4.9% Higher

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) shares traded up 4.9% during trading on Monday . The company traded as high as $29.42 and last traded at $29.26. 90,288 shares changed hands during trading, a decline of 87% from the average session volume of 699,426 shares. The stock had previously closed at $27.88.

Analysts Set New Price Targets

A number of brokerages recently issued reports on TARS. HC Wainwright increased their price objective on Tarsus Pharmaceuticals from $57.00 to $61.00 and gave the stock a “buy” rating in a research report on Monday, May 13th. Barclays raised their price target on Tarsus Pharmaceuticals from $50.00 to $60.00 and gave the company an “overweight” rating in a report on Friday, May 10th. Finally, Oppenheimer boosted their price objective on Tarsus Pharmaceuticals from $59.00 to $61.00 and gave the stock an “outperform” rating in a report on Thursday, May 9th. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $50.38.

Tarsus Pharmaceuticals Stock Performance

The company has a debt-to-equity ratio of 0.11, a current ratio of 8.01 and a quick ratio of 7.92. The company has a 50 day simple moving average of $32.48 and a 200-day simple moving average of $30.87. The firm has a market cap of $1.07 billion, a PE ratio of -5.84 and a beta of 1.05.

Tarsus Pharmaceuticals (NASDAQ:TARS) last announced its quarterly earnings data on Wednesday, May 8th. The company reported ($1.01) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.15) by $0.14. The business had revenue of $27.61 million during the quarter, compared to analysts’ expectations of $17.94 million. As a group, equities research analysts anticipate that Tarsus Pharmaceuticals, Inc. will post -3.75 EPS for the current year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Vanguard Group Inc. grew its holdings in shares of Tarsus Pharmaceuticals by 25.6% in the third quarter. Vanguard Group Inc. now owns 1,551,802 shares of the company’s stock worth $27,576,000 after purchasing an additional 316,128 shares during the last quarter. SG Americas Securities LLC boosted its holdings in shares of Tarsus Pharmaceuticals by 8.4% during the fourth quarter. SG Americas Securities LLC now owns 54,979 shares of the company’s stock worth $1,113,000 after purchasing an additional 4,266 shares during the period. Raymond James Financial Services Advisors Inc. grew its stake in shares of Tarsus Pharmaceuticals by 42.9% in the fourth quarter. Raymond James Financial Services Advisors Inc. now owns 43,819 shares of the company’s stock worth $887,000 after purchasing an additional 13,162 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its holdings in Tarsus Pharmaceuticals by 362.8% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 3,832 shares of the company’s stock valued at $78,000 after purchasing an additional 3,004 shares during the period. Finally, abrdn plc bought a new position in Tarsus Pharmaceuticals during the 4th quarter valued at approximately $1,459,000. Hedge funds and other institutional investors own 90.01% of the company’s stock.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.